Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients

American Journal of Health-System Pharmacy

Volumn 72, Issue 4, 2015, Pages 277-284

  Pennington, Catherine A ^a   Park, Jeong M ^b,c  

^a JACKSON MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOTRIMAZOLE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; KETOCONAZOLE; NYSTATIN; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

DRUG EXPOSURE; DRUG MONITORING; END STAGE RENAL DISEASE; ENTERAL DRUG ADMINISTRATION; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; COMPARATIVE STUDY; META ANALYSIS; ORAL DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; TACROLIMUS;

EID: 84921711292     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp140322     Document Type: Review

References (33)

1. Scientific Registry of Transplant Recipients. Annual data report, 2011. http://www.sr tr.org/annual-reports/2011 (accessed 2014 Aug 8).
2. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004; 43:623-53.
3. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007; 2:374-84.
4. De Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycohenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit. 2009; 31:416-35.
5. Bouamar R, Shuker N, Hesselink DA et al. Tacrolimus predose concetrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials. Am J Transplant. 2013; 13:1253-61.
6. Prograf (tacrolimus capsules, tacrolimus injection) package insert. Deerfield, IL: Astellas Pharma US, Inc.; 2011.
7. Astagraf XL (tacrolimus extended-release capsules) package insert. Deerfield, IL: Astellas Pharma US, Inc.; 2013.
8. McGhee B, McCombs JR, Boyle G et al. Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients. Transplantation. 1997; 64:941-2.
9. Jacobson PA, Johnson CE, West NJ et al. Stability of tacrolimus in an extemporaneously compounded oral liquid. Am J Health-Syst Pharm. 1997; 54:178-80.
10. Elefante A, Muindi J, West K et al. Long-term stability of a patient-convenient 1 mg/mL suspension of tacrolimus for accurate maintenance of stable therapeutic levels. Bone Marrow Transplant. 2006; 37:781-4.
11. Reding R, Sokal E, Paul K et al. Efficacy and pharmacokinetics of tacrolimus oral suspension in pediatric liver transplant recipients. Pediatr Transplant. 2002; 6:124-6.
12. Murray M, Grogan TA, Lever J et al. Comparison of tacrolimus absorption in transplant patients receiving continuous versus interrupted enteral nutritional feeding. Ann Pharmacother. 1998; 32:633-6.
13. Hodak SP, Moubarak JB, Rodriguez I et al. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. Transplantation. 1998; 66:535-7.
14. Abu-Elmagd KM, Fung J, Draviam R et al. Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. Transplant Proc. 1991; 23:2767-70.
15. Taormina D, Abdallah HY, Venkataramanan R et al. Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers. Am J Hosp Pharm. 1992; 49:119-22.
16. Van de Plas A, Dackus J, Christiaans M et al. Rectal administration of tacrolimus: a pilot study. Br J Clin Pharmacol. 2008; 66:741-2. Abstract.
17. Stifft F, Vanmolkot F, Scheffers I et al. Rectal and sublingual administration of tacrolimus: a single dose pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol. 2014; 78:996-1004.
18. Goorhuis JF, Scheenstra R, Peeters PM, Albers MJ. Buccal vs. nasogastric tube administration of tacrolimus after pediatric liver transplantation. Pediatr Transplant. 2006; 10:74-7.
19. Reams D, Rea J, Davis D, Palmer S. Utility of sublingual tacrolimus in cystic fibrosis patients after lung transplantation. J Heart Lung Transplant. 2001; 20:207-8. Abstract.
20. Reams BD, Palmer SM. Sublingual tacrolimus for immunosuppression in lung transplantation: a potentially important therapeutic option in cystic fibrosis. Am J Respir Med. 2002; 1:91-8.
21. Collin C, Boussaud V, Lefeuvre S et al. Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study. Transplant Proc. 2010; 42:4331-7.
22. Stewart S, Fishbein MC, Snell GI et al. Revision of the 1996 working formulation for the standardization in the diagnosis of lung rejection. J Heart Lung Transplant. 2007; 26:1229-42.
23. Watkins KD, Boettger RF, Hanger KM et al. Use of sublingual tacrolimus in lung transplant recipients. J Heart Lung Transplant. 2012; 31:127-32.
24. Romero I, Jimémez C, Gil F et al. Sublingual administration of tacrolimus in a renal transplant patient. J Clin Pharm Ther. 2008; 33:87-9.
25. Tsapepas D, Saal S, Benkert S et al. Sublingual tacrolimus: a pharmacokinetic evaluation pilot study. Pharmacotherapy. 2013; 33:31-7.
26. Tuteja S, Alloway RR, Johnson JA et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation. 2001; 71:1303-7.
27. Hebert MF, Fisher RM, Marsh CL et al. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol. 1999; 39:91-6.
28. Van de Plas A, Dackus J, Christiaans MH et al. A pilot study on sublingual administration of tacrolimus. Transpl Int. 2009; 22:358-9.
29. Nasiri-Toosi Z, Dashti-Khavidaki S, Nasiri-Toosi M et al. Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. Exp Clin Transplant. 2012; 10:586-91.
30. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006; 63:1172-93.
31. National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2012. www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf (accessed 2014 Aug 8).
32. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant. 2001; 16:1905-9.
33. Borobia AM, Romero I, Jimenez C et al. Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther Drug Monit. 2009; 31:436-42.